Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Webcast

Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference


Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 12:30 pm ET in New York, NY.

A webcast of the panel discussion will be available on the "Events & Presentations" section of the Company's website at www.kezarlifesciences.com. Following the event, an archived webcast will be available on the Kezar website for 90 days.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. Zetomipzomib, a selective immunoproteasome inhibitor, is currently being evaluated in a Phase 2b clinical trial for lupus nephritis and a Phase 2a clinical trial for autoimmune hepatitis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. Kezar's oncology product candidate, KZR-261, targeting the Sec61 translocon and protein secretion pathway, is being evaluated in an open-label dose-escalation Phase 1 clinical trial to assess safety, tolerability and preliminary tumor activity in solid tumors. For more information, visit www.kezarlifesciences.com, and follow us on LinkedIn, Facebook, Twitter and Instagram.


These press releases may also interest you

at 22:52
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major...

at 21:00
ZA Tech, the next-generation insurance core system SaaS provider, has rebranded as Peak3. With the successful completion of its US$35 million Series A fundraising from EQT (lead investor) and Alpha JWC Ventures, Peak3 now accelerates its expansion in...

at 21:00
YolTech, a clinical-stage biopharmaceutical company specializing in mRNA-LNP delivery for in vivo gene editing therapies, has partnered with KACTUS, a leading developer serving the biopharmaceutical industry, to advance the commercialization of...

at 21:00
Every year, heat-related visits to emergency rooms in Texas soar to unprecedented levels and many Texans lose their lives as a result of excessively high temperatures but board-certified emergency...

at 19:20
The global human combination vaccines market  size is estimated to grow by USD 7.02 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  8.69%  during the forecast period.  Increasing antiviral drug...

at 19:00
Cannabix Technologies Inc. (the "Company") announces the results of its annual general and special meeting of common shareholders held on June 18, 2024 in Vancouver. Resolutions passed at the meeting included the appointment of Saturna Group...



News published on and distributed by: